Tag: reversible thrombolytic
Basking doses first patients in phase-one study of stroke drug reversal...
Basking Biosciences has announced that the first participants have been dosed in a phase-one clinical study of BB-025—a rapid-acting reversal agent designed to specifically...
Reversible thrombolytic could alleviate US “tribalism” around tPA and help redefine...
Following Basking Biosciences’ recent announcement that the first acute ischaemic stroke patients have received its novel thrombolytic therapy as part of the Phase 2...
